Market Access News | pharmaphorum

News

NICE says yes to BeiGene's Brukinsa after Scottish nay

BeiGene's BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine NHS use in England and Wales to treat Waldenström macroglobulinaemia (WM

News

AstraZeneca's Tezspire for severe asthma gets green light in...

The European Commission has followed the lead of the US FDA and approved AstraZeneca's Tezspire as an add-on maintenance therapy for patients with severe asthma, becoming the first and only

News

Otsuka, Aurinia claim EU okay for oral lupus nephritis drug

Aurinia Pharma and partner Otsuka have secured approval in the EU for Lupkynis, billed as the first oral treatment for active nephritis in patients with the autoimmune disease systemic lupu

News

Novartis nets potential blockbuster approval with sickle cel...

A new drug to treat painful episodes associated with sickle cell disease from Novartis is poised to hit the US market after approval from the FDA.

News

CHMP says yes to Sanofi/AstraZeneca antibody for RSV prevent...

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections.<

News